Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GEN-004, a Pneumococcal Protein Subunit Vaccine, on Colonization Following Intranasal Challenge With S. Pneumoniae
NCT02116998 is registered in ClinicalTrials.gov with Genocea Biosciences, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GEN-004, a Pneumococcal Protein Subunit Vaccine, on Colonization Following Intranasal Challenge With S. Pneumoniae
- Lead sponsor
- Genocea Biosciences, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2014
- Completion date
- April 30, 2016
- Enrollment
- 98 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.